Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Ladenburg Thalmann Downgrades Rhythm Pharmaceuticals to Neutral

Ladenburg Thalmann analyst Michael Higgins downgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) from Buy to Neutral.
byBenzinga Newsdesk
August 4, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Ladenburg Thalmann analyst Michael Higgins downgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) from Buy to Neutral.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Cannabis Movers & Shakers: Plus Products, Arcview Capital, Greenspoon Marder, KetamineOne, Open Book Extracts, Cannabics Pharmaceuticals, Sundial , Flora Growth

By Jelena Martinovic
Today, 5:07 PM
Plus Products Appoints Tara Soltow As VP Of Marketing Cannabis and hemp branded products company Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) has tapped Tara Soltow to serve as vice president of marketing.

CNBX